
|Videos|May 5, 2021
- Modern Retina Summer 2021
- Volume 1
- Issue 1
Analyzing clinical results of dexamethasone implant effect on macular thickness
Author(s)David Hutton, Modern Retina Staff
Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Advertisement
Daniel F. Kiernan, MD, a vitreoretinal surgeon at The Eye Associates, Sarasota, Florida, discusses the highlights of his 2021 ARVO virtual presentation on the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on optical coherence tomography (OCT) testing following vitreoretinal surgery.
Articles in this issue
almost 5 years ago
Pediatric ophthalmologists target inherited retinal diseasesalmost 5 years ago
Gaining a greater understanding of AMDalmost 5 years ago
VEGF and beyond: therapeutic targeting in retinal vascular disordersNewsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5






















